An hydrophobically modified arginine peptide vector system effectively delivers DNA into human mesenchymal stem cells and maintains transgene expression with differentiation.
Kim NY., Choi YB., Kang CI., Kim HH., Yang JM., Shin S.
Laboratory Study, published in J Gene Med (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- J Gene Med (2010)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20821748
- DOI
- 10.1002/jgm.1497
Abstract (original English)
The ability of human mesenchymal stem cells (hMSCs) to differentiate into specific cells holds promise for therapeutic use in cell- or gene-based therapy. Genetic modification of hMSCs by introduction of therapeutic genes is an important tool for successful cell-mediated gene therapy. Similar to most primary cells, hMSCs are difficult to transfect with currently available gene delivery methods. Viral vectors are the most efficient DNA delivery system in stem cells. However, the use of viral vectors has disadvantages involving safety. To overcome these problems, nonviral gene delivery has been studied as an alternative strategy, and the cationic peptide was an efficient vector for transfecting various mammalian cell types. However, little is known about the capacity of this delivery method to transfect to hMSCs. In the present study, we examined the use of a short arginine peptide as a carrier for DNA delivery in hMSCs. Plasmids containing the enhanced green fluorescent protein (EGFP) were transfected into hMSCs by arginine peptide in vitro. pEGFP delivery and EGFP expression were assessed by the fluorescence-activated cell sorting technique. The hydrophobically modified arginine peptide, palmitic acid-R15 (PA-R15), formed a condensed complex with DNA and successfully delivered the gene into hMSCs without compromising cell survival rate. Complexes readily internalized into hMSCs
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.